Hackensack

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Liver and biliary tract cancer2 trials
• Melanoma2 trials
• Multiple myeloma2 trials
• Amyloidosis1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Glioblastoma1 trial
• HIV1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Myeloproliferative neoplasms1 trial
• Sarcoma1 trial

Phase

• Phase 23 trials
• Phase 1/22 trials
• Phase 11 trial
• Phase 31 trial

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Completed1 trial

Lead sponsor

• GlaxoSmithKline5 trials
• Tesaro, Inc.1 trial
• ViiV Healthcare1 trial

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

  NCT07224672· Phase 2· GlaxoSmithKline· Source

  Contact: Pooja Phull (principal investigator)

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

  Contact: Samit Desai (principal investigator)

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· GlaxoSmithKline· Source

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: David Siegel (principal investigator)

• Active, not recruiting

  Extended Access of Momelotinib in Adults With Myelofibrosis

  NCT03441113· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• HIV1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT03544281· Phase 1/2· GlaxoSmithKline· Source